Johnson & Johnson Pre-Tax Profit Margin 2012-2025 | JNJ
Current and historical pre-tax profit margin for Johnson & Johnson (JNJ) from 2012 to 2025. Pre-tax profit margin can be defined as earnings before taxes as a portion of total revenue. Johnson & Johnson pre-tax profit margin for the three months ending September 30, 2025 was .
| Johnson & Johnson Pre-Tax Profit Margin Historical Data | |||
|---|---|---|---|
| Date | TTM Revenue | TTM Pre-Tax Income | Pre-Tax Margin |
| 2025-09-30 | $92.15B | $31.50B | 34.19% |
| 2025-06-30 | $90.63B | $27.35B | 30.18% |
| 2025-03-31 | $89.33B | $26.60B | 29.78% |
| 2024-12-31 | $88.82B | $16.69B | 18.79% |
| 2024-09-30 | $87.70B | $17.63B | 20.10% |
| 2024-06-30 | $86.58B | $19.51B | 22.53% |
| 2024-03-31 | $85.65B | $20.06B | 23.42% |
| 2023-12-31 | $85.16B | $15.06B | 17.69% |
| 2023-09-30 | $76.31B | $12.72B | 16.67% |
| 2023-06-30 | $74.96B | $12.68B | 16.91% |
| 2023-03-31 | $77.46B | $12.21B | 15.76% |
| 2022-12-31 | $79.99B | $19.36B | 24.20% |
| 2022-09-30 | $77.21B | $18.11B | 23.46% |
| 2022-06-30 | $80.55B | $16.79B | 20.84% |
| 2022-03-31 | $79.85B | $17.61B | 22.06% |
| 2021-12-31 | $78.74B | $19.18B | 24.36% |
| 2021-09-30 | $91.45B | $19.59B | 21.42% |
| 2021-06-30 | $89.19B | $20.14B | 22.58% |
| 2021-03-31 | $84.21B | $17.42B | 20.68% |
| 2020-12-31 | $82.58B | $16.50B | 19.98% |
| 2020-09-30 | $80.86B | $19.07B | 23.58% |
| 2020-06-30 | $80.50B | $16.31B | 20.27% |
| 2020-03-31 | $82.73B | $19.42B | 23.47% |
| 2019-12-31 | $82.06B | $17.33B | 21.12% |
| 2019-09-30 | $81.71B | $16.23B | 19.87% |
| 2019-06-30 | $81.33B | $19.01B | 23.37% |
| 2019-03-31 | $81.59B | $16.94B | 20.76% |
| 2018-12-31 | $81.58B | $18.00B | 22.06% |
| 2018-09-30 | $81.38B | $17.44B | 21.43% |
| 2018-06-30 | $80.68B | $17.80B | 22.07% |
| 2018-03-31 | $78.69B | $17.58B | 22.34% |
| 2017-12-31 | $76.45B | $17.67B | 23.12% |
| 2017-09-30 | $74.36B | $19.44B | 26.14% |
| 2017-06-30 | $72.53B | $19.93B | 27.48% |
| 2017-03-31 | $72.17B | $20.08B | 27.83% |
| 2016-12-31 | $71.89B | $19.80B | 27.55% |
| 2016-09-30 | $71.60B | $19.24B | 26.87% |
| 2016-06-30 | $70.88B | $18.08B | 25.51% |
| 2016-03-31 | $70.18B | $18.92B | 26.95% |
| 2015-12-31 | $70.07B | $19.20B | 27.39% |
| 2015-09-30 | $70.52B | $18.14B | 25.73% |
| 2015-06-30 | $71.88B | $20.83B | 28.98% |
| 2015-03-31 | $73.59B | $20.71B | 28.15% |
| 2014-12-31 | $74.33B | $20.56B | 27.66% |
| 2014-09-30 | $74.43B | $20.61B | 27.69% |
| 2014-06-30 | $73.54B | $17.47B | 23.75% |
| 2014-03-31 | $71.92B | $16.63B | 23.13% |
| 2013-12-31 | $71.31B | $15.47B | 21.69% |
| 2013-09-30 | $70.52B | $15.82B | 22.44% |
| 2013-06-30 | $69.99B | $15.75B | 22.50% |
| 2013-03-31 | $68.59B | $12.99B | 18.94% |
| 2012-12-31 | $67.22B | $13.78B | 20.49% |
| 2012-09-30 | $65.92B | $10.99B | 16.68% |
| 2012-06-30 | $64.87B | $11.51B | 17.74% |
| 2012-03-31 | $65.00B | $12.90B | 19.84% |
| 2011-12-31 | $65.03B | $12.36B | 19.01% |
| 2011-09-30 | $64.42B | $14.27B | 22.15% |
| 2011-06-30 | $63.40B | $14.38B | 22.68% |
| 2011-03-31 | $62.13B | $15.18B | 24.43% |
| 2010-12-31 | $61.59B | $16.95B | 27.52% |
| 2010-09-30 | $62.49B | $17.32B | 27.72% |
| 2010-06-30 | $62.59B | $17.35B | 27.72% |
| 2010-03-31 | $62.50B | $17.39B | 27.83% |
| 2009-12-31 | $61.90B | $15.76B | 25.45% |
| 2009-09-30 | $60.53B | $16.67B | 27.54% |
| 2009-06-30 | $61.37B | $16.71B | 27.23% |
| 2009-03-31 | $62.58B | $16.83B | 26.89% |
| 2008-12-31 | $63.75B | $16.93B | 26.56% |
| 2008-09-30 | $64.52B | $15.74B | 24.40% |
| 2008-06-30 | $63.57B | $14.72B | 23.16% |
| 2008-03-31 | $62.25B | $14.38B | 23.10% |
| 2007-12-31 | $61.10B | $13.28B | 21.74% |
| 2007-09-30 | $58.82B | $13.66B | 23.22% |
| 2007-06-30 | $57.14B | $14.05B | 24.59% |
| 2007-03-31 | $55.37B | $13.62B | 24.61% |
| 2006-12-31 | $53.32B | $14.59B | 27.36% |
| 2006-09-30 | $52.25B | $14.38B | 27.52% |
| 2006-06-30 | $51.28B | $14.14B | 27.58% |
| 2006-03-31 | $50.67B | $13.80B | 27.24% |
| 2005-12-31 | $50.51B | $13.12B | 25.97% |
| 2005-09-30 | $50.66B | $12.73B | 25.13% |
| 2005-06-30 | $49.90B | $12.59B | 25.22% |
| 2005-03-31 | $48.62B | $12.75B | 26.23% |
| 2004-12-31 | $47.35B | $12.33B | 26.04% |
| 2004-09-30 | $45.85B | $12.59B | 27.45% |
| 2004-06-30 | $44.75B | $12.26B | 27.40% |
| 2004-03-31 | $43.60B | $10.88B | 24.96% |
| 2003-12-31 | $41.86B | $10.31B | 24.62% |
| 2003-09-30 | $40.01B | $9.78B | 24.45% |
| 2003-06-30 | $38.64B | $9.23B | 23.88% |
| 2003-03-31 | $37.38B | $9.60B | 25.68% |
| 2002-12-31 | $36.30B | $9.29B | 25.60% |
| 2002-09-30 | $35.12B | $8.89B | 25.30% |
| 2002-06-30 | $34.10B | $8.60B | 25.22% |
| 2002-03-31 | $33.21B | $8.30B | 25.00% |
| 2001-12-31 | $32.32B | $7.90B | 24.44% |
| 2001-09-30 | $31.20B | $7.57B | 24.27% |
| 2001-06-30 | $30.58B | $7.30B | 23.87% |
| 2001-03-31 | $30.07B | $7.08B | 23.55% |
| 2000-12-31 | $29.54B | $6.76B | 22.88% |
| 2000-09-30 | $29.30B | $6.66B | 22.73% |
| 2000-06-30 | $28.75B | $6.34B | 22.05% |
| 2000-03-31 | $28.05B | $6.04B | 21.53% |
| 1999-12-31 | $27.47B | $5.75B | 20.94% |
| 1999-09-30 | $27.06B | $4.88B | 18.02% |
| 1999-06-30 | $25.99B | $4.68B | 18.02% |
| 1999-03-31 | $24.89B | $4.44B | 17.84% |
| 1998-12-31 | $24.00B | $4.27B | 17.79% |
| 1998-09-30 | $23.16B | $4.91B | 21.18% |
| 1998-06-30 | $22.93B | $4.79B | 20.87% |
| 1998-03-31 | $22.75B | $4.71B | 20.69% |
| 1997-12-31 | $22.63B | $4.58B | 20.22% |
| 1997-09-30 | $22.50B | $3.40B | 15.11% |
| 1997-06-30 | $22.32B | $3.26B | 14.62% |
| 1997-03-31 | $22.00B | $4.21B | 19.14% |
| 1996-12-31 | $21.62B | $4.03B | 18.65% |
| 1996-09-30 | $20.96B | $5.02B | 23.94% |
| 1996-06-30 | $20.30B | $4.83B | 23.80% |
| 1996-03-31 | $19.68B | $3.52B | 17.89% |
| 1995-12-31 | $18.84B | $3.32B | 17.60% |
| 1995-09-30 | $18.09B | $3.19B | 17.66% |
| 1995-06-30 | $17.39B | $3.04B | 17.46% |
| 1995-03-31 | $16.54B | $2.87B | 17.33% |
| 1994-12-31 | $14.97B | $2.68B | 17.91% |
| 1994-09-30 | $14.41B | $2.59B | 17.98% |
| 1994-06-30 | $13.88B | $2.46B | 17.72% |
| 1994-03-31 | $13.51B | $2.37B | 17.53% |
| 1993-12-31 | $14.14B | $2.33B | 16.49% |
| 1993-09-30 | $14.11B | $2.25B | 15.97% |
| 1993-06-30 | $14.08B | $2.26B | 16.03% |
| 1993-03-31 | $13.96B | $2.24B | 16.07% |
| 1992-12-31 | $13.75B | $2.21B | 16.05% |
| 1992-09-30 | $13.40B | $2.23B | 16.67% |
| 1992-06-30 | $13.04B | $2.17B | 16.64% |
| 1992-03-31 | $12.66B | $2.09B | 16.54% |
| 1991-12-31 | $12.45B | $2.04B | 16.37% |
| 1991-09-30 | $12.00B | $2.00B | 16.63% |
| 1991-06-30 | $11.75B | $1.91B | 16.25% |
| 1991-03-31 | $11.54B | $1.83B | 15.85% |
| 1990-12-31 | $11.23B | $1.62B | 14.45% |
| 1990-09-30 | $11.00B | $1.58B | 14.39% |
| 1990-06-30 | $10.59B | $1.51B | 14.27% |
| 1990-03-31 | $10.15B | $1.45B | 14.29% |
| 1989-12-31 | $9.76B | $1.51B | 15.52% |
| 1989-09-30 | $9.49B | $1.50B | 15.77% |
| 1989-06-30 | $9.23B | $1.48B | 16.00% |
| 1989-03-31 | $9.13B | $1.46B | 15.94% |
| 1988-12-31 | $9.00B | $1.40B | 15.51% |
| 1988-09-30 | $8.73B | $1.38B | 15.74% |
| 1988-06-30 | $8.57B | $1.34B | 15.67% |
| 1988-03-31 | $8.34B | $1.25B | 15.01% |
| 1987-12-31 | $8.01B | $1.19B | 14.90% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $529.009B | $88.821B |
| Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $976.553B | 46.97 |
| AbbVie (ABBV) | United States | $383.081B | 22.94 |
| Roche Holding AG (RHHBY) | Switzerland | $344.774B | 0.00 |
| Novartis AG (NVS) | Switzerland | $302.393B | 16.03 |
| Merck (MRK) | United States | $275.430B | 12.83 |
| Novo Nordisk (NVO) | Denmark | $255.041B | 14.95 |
| Pfizer (PFE) | United States | $147.203B | 8.09 |
| Sanofi (SNY) | France | $115.780B | 11.20 |
| Bayer (BAYRY) | Germany | $47.824B | 8.39 |
| Innoviva (INVA) | United States | $1.477B | 7.40 |